The Symplicity HTN-2 trial is an international, multi-center, prospective, randomized, controlled study of renal denervation in patients with treatment-resistant hypertension.
For one, the groups noted the analysis is a retrospective study, not a prospective, randomized controlled clinical trial, which many regard as a gold standard for ferreting out safety concerns.